



LASA SUPERGENERICS LIMITED

CORPORATE OFFICE: B/207, City Point, Near Kohinoor Hotel, J B Nagar (Chakala) Metro Station, Andheri (E), Mumbai – 400059, Maharashtra, India.
Tel: 022-4970 1092, Email: mail@lasalabs.com, Website: www.lasalabs.com

Ref. No.: LASA/SE/20-21/34

Wednesday November 04, 2020

To, Corporate Services Department BSE Limited Phiroze Jeejeebhoy Towers, Dalal Street, Mumbai – 400 001. BSE CODE –540702	To, Corporate Services Department National Stock Exchange of India Limited “Exchange Plaza”, Plot No. C/1, G Block Bandra-Kurla Complex, Bandra (E), Mumbai – 400 051. NSE CODE: LASA
--	--

Sub: **Press Release**

Dear Sir,

Attached is a copy of Press Release titled “**Lasa Supergenerics Receives Environmental Clearance for Benzimidazole Derivatives Capacity Expansion in Unit 2 Located at Khed**”.

You are requested to note the above on your records.

Thanking You.

Yours faithfully,

FOR LASA SUPERGENERICS LIMITED




NIDHI KULSHRESHTHA
COMPANY SECRETARY AND COMPLIANCE OFFICER



Lasa Supergenerics Receives Environmental Clearance for Benzimidazole Derivatives Capacity Expansion in Unit 2 Located at Khed

Lasa's total volumetric capacity to increase by ~60% to 6,800 TPA through de-bottlenecking

Mumbai, November 04, 2020: Lasa Supergenerics Limited (Lasa), India's leading API manufacturer, announced that it has received the 'environmental clearance' from the State Environment Impact Assessment Authority (SEIAA) for expanding its 'benzimidazole derivatives' capacity at the company's manufacturing facility at Khed, Maharashtra.

The proposed expansion will require only a de-bottlenecking capex as the company already has the necessary infrastructure and machinery in place and was awaiting environmental clearance to operationalize the assets.

Post the successful de-bottlenecking, the company's volumetric capacity will increase by 2,500 TPA (rated capacity by 650 TPA) taking the company's total volumetric capacity to 6,800 TPA (total rated capacity of 2,500 TPA). The expanded capacity will be used to manufacture the benzimidazole derivatives (such as Albendazole, Fenbendazole and others) of which Lasa is one of the prominent suppliers. The enhanced capacity is expected to be commissioned in Q3 FY21 and likely to contribute to the top-line from Q4 FY21 onwards.

Commenting on this development, Dr. Omkar Herlekar, Chairman & Managing Director, Lasa Supergenerics said "Receiving the Environmental Clearance for capacity expansion is a significant milestone for fulfilling Lasa's expansion plans. Now, we will be able to increase our manufacturing capacity from existing 4,300 TPA to 6,800 TPA post the successful commissioning of the proposed expansion at our state-of-the-art WHO-GMP certified API manufacturing facility in Khed, Maharashtra.

Furthermore, as we already have the necessary infrastructure & machinery in place, the proposed expansion will require only a de-bottlenecking capex of approximately INR 3 crores. The expanded capacity is expected to be commissioned in Q3 FY21 and likely to start contributing to the overall revenue from Q4 FY21 onwards. The enhanced capacity at peak utilization can potentially generate sizeable incremental revenue.

About Lasa Supergenerics Limited (www.lasalabs.com/; BSE: 540702; NSE: LASA)

Incorporated in 2011, Lasa is a globally well-trusted API maker of high-quality products accepted by large pharma majors across the globe. The Company is a pioneer and amongst the leading players in the manufacturing of Veterinary APIs, with a well-established brand known for its high-quality products amongst various customers. The Company has three state-of-the-art manufacturing facilities located at Mahad & Chiplun, Maharashtra with a total installed capacity of 4,300 MT. The Company is steadily diversifying into hormonal APIs for human use. Approximately 20% of its APIs are exported to countries such as Australia, Bangladesh, Middle East, China, Turkey, Egypt, Jordan, Korea, and Pakistan.



DISCLAIMER: Certain statements that are made in the Press Release may be forward-looking statements. Such forward looking statements are subject to certain risks and uncertainties like significant changes in economic environment in India and overseas, tax laws, inflation, litigation, etc. Actual results might differ substantially from those expressed or implied. Lasa Supergenerics Ltd. will not be in any way responsible for any action taken based on such statements and discussions; and undertakes no obligation to publicly update these forward-looking statements to reflect subsequent events or circumstances.

For more information, please contact:

Hitesh Wadhvani

Vice President - Legal, Lasa Supergenerics Limited

Tel: +91 7798888147

E-Mail: hitesh@lasalabs.com